À retenir
Pooling 35 randomised trials, programs built around consumer activity trackers raised physical activity by 2123 steps per day (95% CI 1605-2641) and modestly lowered systolic blood pressure, waist circumference and LDL cholesterol. The programs mostly included counselling, and the abstract does not say how much the tracker itself contributed.
Study design
Méta-analyse d’essais
Reading basis
Published abstract
Reading focus
Design & applicability
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
Consumer activity trackers are popular, but it was unclear whether tracker-based programs help people with chronic disease be more active and improve their health in daily life. The authors pooled randomised trials to test the effect on physical activity and cardiometabolic health.
Population et méthode
Systematic review and meta-analysis of randomised controlled trials. Five databases (PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials and CINAHL) yielded 8147 records after deduplication, of which 35 studies were included. They compared a tracker-based counselling intervention with a control in people with chronic respiratory diseases (7 studies), type 2 diabetes (12), cardiovascular diseases (6), overweight/obesity (3), cognitive disorders (1) or sedentary older adults (6). Data were pooled with a random-effects model.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Physical activity rose by 2123 steps per day compared with controls (95% CI 1605-2641; P < 0.001).
- 2Systolic blood pressure fell by 3.79 mm Hg (95% CI -4.53 to -3.04; P < 0.001).
- 3Waist circumference fell by 0.99 cm (95% CI -1.48 to -0.50; P < 0.001).
- 4LDL cholesterol fell by 5.70 mg/dl (95% CI -9.24 to -2.15; P = 0.002).
Limites et incertitude
- 1Interventions included counselling or behavioural components, so the benefit cannot be credited to the wearable alone.
- 2Populations ranged from 12 type 2 diabetes studies down to a single cognitive disorder study, so evidence is uneven across conditions.
- 3The abstract does not report heterogeneity, trial quality, or how long benefits lasted.
- 4This reading is based on the abstract only.
Mise en perspective
Using a tracker as part of a structured program was linked to meaningfully more daily steps, and small improvements in blood pressure and cholesterol, in people with chronic conditions. These blood pressure and cholesterol changes are modest, so they complement and do not replace treatment. Anyone with a chronic disease should check with their clinician before changing their activity level.
Vos données
Daily step count is exactly what these programs targeted. Wear the same device consistently, note your usual weekly average first, and set goals as increases over that baseline rather than chasing single days.
Comprendre ce type de preuve
Pooling trials can improve precision, but compare populations, controls, bias and uncertainty. Network rankings include indirect evidence and do not identify a universal best treatment.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Background
To date, it is unclear if consumer wearable activity trackers (CWATs), with or without behaviour multi-component strategies, effectively improve adherence to physical activity and health outcomes under free living conditions in populations with chronic diseases. Therefore, we systematically evaluated the efficacy of CWAT-based interventions to promote physical activity levels and cardiometabolic health in populations with chronic diseases.
Methods
Randomised controlled trials were collected from five bibliographic databases (PubMed, Embase, Web of Science, The Cochrane Central Register of Controlled Trials and CINAHL). Studies were eligible for inclusion if they evaluated a CWAT-based counselling intervention versus control intervention among patients with chronic respiratory diseases, type 2 diabetes mellitus, cardiovascular diseases, overweight/obesity, cognitive disorders, or sedentary older adults. Data were pooled using a random-effects model.
Results
After deduplication 8147 were identified of which 35 studies met inclusion criteria (chronic respiratory diseases: 7, type 2 diabetes mellitus: 12, cardiovascular diseases: 6, overweight/obesity: 3, cognitive disorders: 1, sedentary older adults: 6). Compared to control groups, CWAT-based interventions significantly increased physical activity by 2123 steps per day (95% confidence interval [CI], [1605-2641]; p < 0.001). In addition, CWAT-based interventions in these populations significantly decreased systolic blood pressure (- 3.79 mm Hg; 95% CI: [- 4.53, - 3.04] mm Hg; p < 0.001), waist circumference (- 0.99 cm; 95% CI: [- 1.48, - 0.50] cm; p < 0.001) and low-density lipoprotein cholesterol concentration (- 5.70 mg/dl; 95% CI: [- 9.24, - 2.15] mg/dl; p = 0.002).
Conclusion
CWAT-based interventions increase physical activity and have beneficial effects on important health-related outcomes such as systolic blood pressure, waist circumference and LDL cholesterol concentration in patients with chronic diseases.
Sources et attribution
Can consumer wearable activity tracker-based interventions improve physical activity and cardiometabolic health in patients with chronic diseases? A systematic review and meta-analysis of randomised controlled trials.
Franssen WMA, Franssen GHLM, Spaas J, Solmi F, Eijnde BO.
The international journal of behavioral nutrition and physical activity · 2020-05-11
DOI: 10.1186/s12966-020-00955-2 ↗PubMed · 32393357 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
Activity–stroke and heart attack curves differ by accelerometer processing method
Among 90,237 UK Biobank adults free of cardiovascular disease at baseline, followed until December 2022 for 1,298 strokes and 2,031 myocardial infarctions, the shape of the link between moderate-vigorous physical activity (MVPA) and each outcome depended on how the accelerometer data were processed. For stroke, hazard fell in a straight line only with the machine-learning metric; for myocardial infarction, two metrics gave a curved decline and activity counts a straight one. The abstract gives no hazard ratios, so it shows that methods disagree, not which one is right, and the findings are observational associations.
Preventive Medicine
Smartwatch data as forensic evidence: heart rate is best validated, the rest uneven
A systematic review and meta-analysis of studies on smartwatches from four major brands, framed around digital forensics, found that heart rate was both the most studied and the most accurate measure. Step count, distance, energy expenditure, activity classification and sleep were less consistently validated, and results varied by brand, protocol and reporting. The abstract gives no pooled numbers, and most studies were run in healthy people in laboratories, so it cannot say how a particular watch performs for a particular person in daily life.
Forensic Science International
Activity trackers: about 1,800 more steps a day, but small effects on other outcomes
An umbrella review of 39 systematic reviews and meta-analyses, covering 163,992 participants, found that activity trackers were associated with more physical activity (SMD 0.3–0.6), equating to about 1,800 extra steps and 40 minutes more walking per day, and with a bodyweight reduction of about 1 kg. Effects on blood pressure, cholesterol, glycosylated haemoglobin, quality of life and pain were typically small and often non-significant. The abstract does not say what else came with the trackers in these programs or how much the reviews overlap, so the gains cannot be credited to the device alone.
The Lancet Digital Health
Seven sleep trackers: good at spotting sleep, weak on wake and sleep stages
In a sleep laboratory, 34 healthy young adults wore a subset of seven consumer sleep trackers for three nights. Against polysomnography every device detected sleep very well (sensitivity 0.93 or higher) but caught wake poorly (specificity 0.18–0.54), and five of the seven matched or beat research actigraphy (specificity 0.39). Sleep-stage estimates were inconsistent, and the participants were healthy adults aged 18 to 35 in a fixed 8-hour bed window, with each device tested in only 11 to 20 of them, so the results say little about people with sleep problems.
Sleep

